Trial Profile
COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Zorecimeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors CureVac
- 20 Apr 2022 Status changed from completed to discontinued.
- 05 Oct 2021 Status changed from active, no longer recruiting to completed.
- 16 Aug 2021 According to a CureVac media release, the study will continue with a reduced number of 131 recruited participants.